Enzolytics Inc. announced that the Company's representative traveled to Africa to arrange for the delivery of its ITV-1 immunotherapy treatments to African hospitals and to finalize the information to be included on product labels as required by the African regulatory agencies. The anti-HIV treatment consists of two 8-week cycles of 16 injections with a one-week break, totaling a 17-week treatment period. After the delivery of the vials, the hospitals will administer the treatments over the 17-week treatment period and periodically provide ENZC with clinical data of its effectiveness.

Once the initial patients are treated and when ITV-1 demonstrates effectiveness, the Company expects to provide additional treatments to treat up to 30,000 additional patients living in the Central and Eastern region of Africa. ENZC has received a response from the European Medicines Agency informing the Company that the required method for pharmacokinetics study will be in accordance with ELAZA standards. The Bulgarian Academy of Science will be providing the following studies on ITV-1: 1) determination of the protein concentration in the initial sample using the Bradford method, 2) electrophoretic analysis, 3) determination of the concentration of the native enzyme in samples, 4) HPLC analysis, 5) analysis of the peptides obtained after hydrolysis in samples using a UHPLC-Q-TOF mass spectrometer system including the Bruker Impact HD Q-TOF system equipped with a Captive Spray nano Booster ionization source and compass 1.7 software.

Lachezar Ivanov will continue to operate under the direction of Dr. Gaurav Chandra as Chairman and CEO and Charles Cotropia as BGEN Director. BGEN will continue to pursue production of species-specific monoclonal antibodies (mAbs) and continued advancement in its disruptive proprietary technology involving the application of Artificial Intelligence (AI) in therapeutic discoveries and production. VIRO will continue to be managed by Diana Zhabilov as Chairma.